In a further pushback against the Institute for Clinical and Economic Review's cost-effectiveness assessment of new multiple myeloma treatments, an advocacy group has come up with a calculation of how many lives would be lost under the benchmark.
The Center for Medicine in the Public Interest looked at the historical rate of access to second and third line...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?